Associated Papers
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis.
Shen L et al.
Cancer Medicine, 2025
[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations in Non-small Cell Lung Cancer].
Zhao J et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2025
Case Series: EGFR and ROS-1 Co-Occurrence in Advanced Non-Small Cell Lung Cancer.
Alfayea T et al.
Journal of Immunotherapy and Precision Oncology, 2024
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18-18 and EGFR amplification: A case report.
Wang P et al.
Frontiers in Oncology, 2022
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Rational design of non-resistant targeted cancer therapies.
Martínez-Jiménez F et al.
Scientific Reports, 2017
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
Ivanov M et al.
Journal of Translational Medicine, 2017
Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.
Froyen G et al.
Plos One, 2016
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China.
Gou LY et al.
Lung Cancer (auckland, N.z.), 2014
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.
An SJ et al.
Plos One, 2012
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.
Huang YS et al.
Chinese Medical Journal, 2011
Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.
Zhang GC et al.
Clinical Oncology (royal College of Radiologists (great Britain)), 2007
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Yun CH et al.
Cancer Cell, 2007
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].
Xu CR et al.
Zhonghua Yi Xue Za Zhi, 2006